Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Economic Affairs Director Of Japan’s MHLW Comments On Daiichi Sankyo's Buyout Of Ranbaxy

This article was originally published in PharmAsia News

Executive Summary

Commenting on Daiichi Sankyo's buyout of Ranbaxy, Toshihiko Takeda, the economic affairs director of the Ministry of Health, Labor and Welfare's Health Policy Bureau, said he was surprised but thought as a new drug developer, Daiichi Sankyo took a step in the right direction to further expand overseas in a more competitive market. Even though it is still too early to judge how the generics market will develop in Japan, if after the merger Daiichi Sankyo decides to enter the generics market in Japan, it will have credibility as a major drug maker combined with low production costs in India. The legitimacy of the company's generics unit could contribute to the expansion of generic utilization in Japan. (Click here for more - Japanese language) "Economic Affairs Director Toshihiko Takeda Comments on Daiichi Sankyo's Buyout Of Ranbaxy" - Yakuji News (6/11/08)

You may also be interested in...

What Justice Ginsburg’s Death Means For Pharma

A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts